TRVI
TRVI clinical trials: Trevi Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Trevi Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 18
- Trials linked
- 18
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
TRVI on the catalyst calendar · TRVI registry changes
- Primary completion Nov 30, 2026Sponsor estimatePhase 1NCT07946575A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in...Trevi Therapeutics · Healthy ParticipantsRecruitingTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 3NCT07868419Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) TabletsTrevi Therapeutics · Idiopathic Pulmonary FibrosisRecruitingTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 3NCT07671911Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) TabletsTrevi Therapeutics · Idiopathic Pulmonary FibrosisRecruitingTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 2NCT07671924The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)Trevi Therapeutics · Refractory Chronic CoughRecruitingTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2026ActualPhase 1NCT07487740A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy ParticipantsTrevi Therapeutics · Healthy ParticipantsCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2026ActualPhase 1NCT07036029NAL ER IPF Respiratory Function and Safety StudyTrevi Therapeutics · Idiopathic Pulmonary FibrosisCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 24, 2025ActualPhase 2NCT05964335Cough Reduction in IPF With Nalbuphine ERTrevi Therapeutics · Idiopathic Pulmonary FibrosisCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2025ActualPhase 2NCT05962151Refractory Chronic Cough Improvement Via NAL ER (RIVER)Trevi Therapeutics · Refractory Chronic CoughCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2020ActualPhase 1NCT04020016Study of Nalbuphine ER in Participants With Hepatic ImpairmentTrevi Therapeutics · Hepatic ImpairmentCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 12, 2025ActualPhase 1NCT07015398A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy ParticipantsTrevi Therapeutics · Healthy ParticipantsCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 10, 2022ActualPhase 2/Phase 3NCT03497975PRISM Study-Pruritus Relief Through Itch Scratch ModulationTrevi Therapeutics · Prurigo NodularisCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2018ActualPhase 1NCT04018664Oral Abuse Potential Study of NalbuphineTrevi Therapeutics · NalbuphineCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2013ActualPhase 1NCT02373215Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic PruritusTrevi Therapeutics · Uremic PruritusCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 3, 2017ActualPhase 2/Phase 3NCT02174432Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo NodularisTrevi Therapeutics · Prurigo NodularisCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2016ActualPhase 2/Phase 3NCT02174419Study of Nalbuphine HCl ER Tablets in Patients With Prurigo NodularisTrevi Therapeutics · Prurigo NodularisCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2016ActualPhase 2/Phase 3NCT02143973Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic PruritusTrevi Therapeutics · Uremic PruritusCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2015ActualPhase 2/Phase 3NCT02143648Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic PruritusTrevi Therapeutics · Uremic PruritusCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 27, 2022ActualPhase 2NCT04030026A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of CoughTrevi Therapeutics · Idiopathic Pulmonary FibrosisCompletedTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 18 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner